Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2025-04-24 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
关于举行2024年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding the 2024 annual online performance briefing (业绩说明会) by the company 南京药石科技股份有限公司. It invites investors to participate and submit questions in advance. The document does not contain any financial data or detailed report content but is a notice about the upcoming event. This fits the category of an Investor Presentation (IP) since it is a detailed presentation event focusing on financial results and company performance for investors.
2025-04-24 Chinese
关于2024年计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the 2024 asset impairment provisions it has made. It details the amounts and types of impairment (credit loss, inventory write-down, goodwill impairment), the accounting standards and methods used, and the impact on the company's financials. The document is relatively short (2002 characters) and is a formal disclosure of an accounting adjustment rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or a regulatory compliance filing. The content is focused on the impairment provision announcement, which is a specific financial update but not a full earnings release or capital update. Given the nature and length, this fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2025-04-24 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '南京药石科技股份有限公司2025 年第一季度报告' which translates to 'Nanjing Yaoshi Technology Co., Ltd. 2025 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2025-04-24 Chinese
2024年度独立董事述职报告（江希和）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It is a detailed report by an independent director about their duties, attendance, and activities during the year 2024. The content focuses on the director's role, meetings attended, communication with auditors, and oversight activities. It does not contain financial statements or financial performance data, nor is it an announcement or notice. It is a management-related report focusing on governance and director duties. This fits best under Board/Management Information (MANG) as it relates to the independent director's report on their management and supervisory role within the company. The document length is 3529 characters, which is relatively short but contains substantive content about management activities rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2025-04-24 Chinese
董事会审计委员会对会计师事务所2024年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance of the accounting firm for the 2024 fiscal year audit. It discusses the audit firm's qualifications, the audit process, communication with auditors, and the committee's supervision of the audit work. The document references the 2024 annual audit and the audit report issued by the accounting firm, but it is not the audit report itself. It is a supervisory and evaluation report by the audit committee on the auditor's performance and the audit process. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related evaluations by internal committees. The document is not an Annual Report (10-K) because it does not contain full financial statements or comprehensive company activity details. It is not a Regulatory Filing (RNS) because it is a substantive report on audit oversight, not a certification or miscellaneous announcement. The document length is 2092 characters, which is sufficient for a detailed report but not a brief announcement. Therefore, the best classification is AR with high confidence.
2025-04-24 Chinese
2024年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2024 by 南京药石科技股份有限公司. It details the company's internal control evaluation, covering financial and non-financial controls, risk management, governance structure, and compliance with regulatory frameworks. The document includes detailed descriptions of internal control systems, risk assessments, control activities, and audit oversight. It is a comprehensive report on the company's internal control effectiveness and compliance, not merely an announcement or a brief summary. The length (over 10,000 characters) and content indicate it is a full report rather than a notice or certification. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluations, distinct from full annual reports or interim financial statements. Therefore, the appropriate classification is AR with high confidence.
2025-04-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.